Welcome to our dedicated page for Ligand Pharma news (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharma stock.
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is a biopharmaceutical company that regularly issues news about its royalty portfolio, technology platforms and capital deployment. The company describes its model as enabling the clinical development of high‑value medicines by providing financing, licensing its technologies, or both, and this approach is reflected in its press releases and investor communications.
News about Ligand often covers financial results and guidance, including updates on total core revenue, royalty revenue, Captisol sales, contract revenue and non‑GAAP measures such as core adjusted earnings per diluted share. The company’s announcements highlight how royalty revenue from partnered products such as Filspari, Ohtuvayre, Capvaxive, Qarziba and Zelsuvmi contributes to its outlook, as well as how deployable capital and new royalty investments are expected to influence long‑term royalty receipts.
Investors following LGND news will also see updates on Ligand’s technology platforms and partner programs. Releases describe Captisol‑enabled approvals like Lasix ONYU, developments in programs such as Qtorin rapamycin, and clinical or regulatory milestones reported by partners that may affect Ligand’s royalty streams. In addition, the company reports on financing transactions, including convertible senior notes offerings and amendments to its credit agreement, which provide context on how Ligand funds royalty acquisitions and other strategic investments.
Corporate events such as Investor Day presentations and participation in healthcare and biopharma conferences are another recurring theme in Ligand’s news flow. These events typically feature discussions of strategy, investment activity, the royalty portfolio and long‑term financial outlook. For investors and observers, the LGND news page offers a centralized view of how Ligand’s royalty‑focused business model, technology licensing and capital allocation decisions evolve over time.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced its participation in the Stifel 2024 Healthcare Conference in New York. CEO Todd Davis and CFO Tavo Espinoza will deliver a presentation on Tuesday, November 19, 2024, at 12:40 p.m. Eastern Time. The company's management team will also be available for one-on-one meetings with investors and conference attendees. Interested investors should contact their Stifel representative to schedule meetings.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced plans to host an Investor and Analyst Day in Boston on December 10, 2024, from 10:30 a.m. to 12:00 p.m. Eastern Time. The event will feature presentations from senior management covering company strategy, investment activities, royalty portfolio, and long-term financial outlook. Key features include an in-person format, a live Q&A session, and accessibility via webcast through Ligand's Investor Relations website. A replay will be available after the event.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced it will release its third quarter 2024 financial results before U.S. markets open on Thursday, November 7, 2024. The company will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) the same day to discuss results and provide a business update. The call will be accessible via phone and webcast, with both live and replay options available.
Ligand Pharmaceuticals (Nasdaq: LGND) announced that its partner Travere Therapeutics received full FDA approval for FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. This approval is based on positive long-term results from the PROTECT Study, showing FILSPARI significantly slowed kidney function decline over two years compared to irbesartan.
Key points:
- FILSPARI is the only non-immunosuppressive treatment for IgAN
- Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI
- FILSPARI demonstrated superior long-term kidney function preservation compared to irbesartan
- The FDA-approved label includes two-year efficacy data
Ligand's CEO, Todd Davis, expressed optimism about FILSPARI's potential as a significant revenue driver for the company in the coming years.
Ligand Pharmaceuticals (Nasdaq: LGND) announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York. CEO Todd Davis and CFO Tavo Espinoza will present on Tuesday, September 10, 2024, at 8:30 a.m. Eastern Time.
The management team is also scheduled to host one-on-one meetings with investors and attendees during the conference. Interested investors should contact their H.C. Wainwright representative to arrange these meetings.
This event provides an opportunity for Ligand to showcase its business and engage with potential investors, potentially impacting the company's stock performance and investor relations.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced it will report its second quarter 2024 financial results after the U.S. financial markets close on Tuesday, August 6, 2024. The company will also hold a conference call at 4:30 p.m. Eastern Time on the same day to discuss the financial results and provide a general business update. Interested parties can join the conference call using the provided phone numbers or access the live and replay webcasts online. This announcement sets the stage for investors and analysts to gain insights into Ligand's financial performance and future outlook.
Ligand Pharmaceuticals (Nasdaq: LGND) will acquire APEIRON Biologics AG for $100 million in cash, gaining royalty rights to QARZIBA®, an oncology drug for high-risk neuroblastoma marketed in 35 countries.
This acquisition will immediately increase Ligand's EPS by $1.00 annually and increase 2024 adjusted EPS guidance by 17% to $5.00-$5.50. Additional consideration up to $28 million may be paid to APEIRON based on future QARZIBA royalties by 2030 or 2034.
Ligand's 2024 revenue guidance is raised to $140 million-$157 million, and royalties expected to range from $100 million-$105 million. The transaction, approved by both companies' boards, is expected to close in July 2024.
Ligand Pharmaceuticals announced that its partner, Verona Pharma, received FDA approval for Ohtuvayre™ (ensifentrine), the first inhaled novel mechanism of action drug for COPD maintenance treatment in over 20 years. Ligand will receive a $5.8 million milestone payment and an additional $13.8 million upon commercial launch in Q3 2024. Ligand is also entitled to a low single-digit royalty on worldwide net sales of Ohtuvayre.
This marks Ligand's second FDA approval within a fortnight and the eighth since 2023. Ohtuvayre targets the multi-billion-dollar COPD market in the U.S. and is expected to bolster Ligand’s growth. The drug combines bronchodilator and non-steroidal anti-inflammatory effects, delivered via a standard jet nebulizer, enhancing ease of use for patients.
Ligand Pharmaceuticals announced that its collaborator Merck has received FDA approval for CAPVAXIVE™, a 21-valent pneumococcal conjugate vaccine for adults. This marks the sixth FDA-approved product utilizing Ligand's Pfenex Expression Technology® platform. Merck's approval triggers a $2 million milestone payment to Ligand, which is also entitled to royalties on global net sales. CAPVAXIVE, previously known as V116, is intended to prevent invasive pneumococcal disease and pneumonia. The PeliCRM197® carrier protein, enhancing antigen immunogenicity, is a key component of this vaccine. Ligand continues to collect commercial royalties on products developed with its technology, including CAPVAXIVE.
Ligand Pharmaceuticals (Nasdaq: LGND) announced the participation of its CEO, Todd Davis, and CFO, Tavo Espinoza, in two upcoming investor conferences. The company will attend the Craig-Hallum Institutional Investor Conference in Minneapolis on May 29, 2024, where management will hold one-on-one meetings with investors. Additionally, Ligand will present at the Goldman Sachs Global Healthcare Conference in Miami on June 12, 2024, at 4:00 p.m. ET, and will also be available for one-on-one meetings. Interested investors should contact their respective institutional equity sales representatives at Craig-Hallum or Goldman Sachs.